GENERIC NAME AVAILABLE AS SULFONYLUREAS Acetohexamide‡ Generic, Dymelor Chlorpropamide Generic, Diabinese Gliclazide‡ Generic, Diamicron Glimepiride Generic, Amaryl Glipizide Generic, Glucotrol, Glucotrol XL Glyburide Generic, Diaβeta, Micronase, Glynase PresTab Tolazamide Generic, Tolinase Tolbutamide Generic, Orinase MEGLITINIDES Repaglinide Generic, Prandin Mitiglinide‡ DPHENYLALANINE DERIVATIVE Nateglinide Generic, Starlix BIGUANIDE Metformin Generic, Glucophage, Glucophage XR METFORMIN COMBINATIONS† Glipizide plus metformin Generic, Metaglip Glyburide plus metformin Generic, Glucovance Pioglitazone plus metformin ACTOplus Met Repaglinide plus metformin Prandi-Met Rosiglitazone plus metformin Avandamet Saxagliptin plus metformin Kombiglyze Sitagliptin plus metformin Janumet Linagliptin plus metformin Jentadueto Alogliptin plus metformin Kazano Dapagliflozin plus metformin Xigduo Canagliflozin plus metformin Invokamet Empagliflozin plus metformin Synjardy THIAZOLIDINEDIONE DERIVATIVES Pioglitazone Generic, Actos Rosiglitazone Avandia ALPHA-GLUCOSIDASE INHIBITORS Acarbose Generic, Precose GENERIC NAME AVAILABLE AS THIAZOLIDINEDIONE COMBINATION Pioglitazone plus glimepiride Duetact Alogliptin plus pioglitazone Oseni Rosiglitazone plus glimepiride Avandaryl Miglitol Glyset Voglibose‡ GLUCAGON-LIKE POLYPEPTIDE-1 RECEPTOR AGONISTS Exenatide Byetta Liraglutide Victoza Albiglutide Tanzeum, Eperzan Dulaglutide Trulicity DIPEPTIDYL PEPTIDASE-4 INHIBITORS Linagliptin Tradjenta Saxagliptin Onglyza Sitagliptin Januvia Alogliptin Nesina Vildagliptin‡ SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITORS Canagliflozin Invokana Dapagliflozin Farxiga Empagliflozin Jardiance SODIUM GLUCOSE CO-TRANSPORTER INHIBITORS COMBINATION Empagliflozin plus linagliptin Glyxambi ISMISCELLANEOUS DRUGSLET AMYLOID POLYPEPTIDE ANALOG Pramlintide Symlin BILE ACID SEQUESTRANT Colesevelam hydrochloride Welchol DOPAMINE RECEPTOR AGONIST Bromocriptine Generic, Parlodel, Cycloset GLUCAGON Glucagon Generic *See Table 41–5 for insulin preparations.
†Other combinations are available.
‡Not available in the United States.
Action to Control Cardiovascular Risks in Diabetes Study Group: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545.
Adler AI et al: Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study. Br Med J 2000;321:412.
ADVANCE Collaborative Group: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560.
Ahmadian M et al: PPARγ signaling and metabolism: The good, the bad and the future. Nat Med 2013;19:557.